Stocks › CGON

CG Oncology, Inc.

CGON·Nasdaq·United States United States·USD
$79.47
-2.43 (-2.97%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
CGON
CG Oncology, Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
CGONS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of CGON by members of U.S. Congress · 0 on record

No congressional trades in CGON on record.

Whale Activity

Position changes in CGON reported for 2026-09-30 by 263 institutional filers
Increased: 84New: 37Held: 32Decreased: 70Closed: 30No prior filing: 10
  • Increased84
  • New37
  • Held32
  • Decreased70
  • Closed30
  • No prior filing10
FilerSharesValueChange
RTW INVESTMENTS, LP8.5M$603.6Mheld
T. Rowe Price Investment Management, Inc.6.7M$476.9Mincreased
Decheng Capital LLC6.4M$451.7Mheld
BlackRock, Inc.6.3M$450.0Mincreased
WELLINGTON MANAGEMENT GROUP LLP4.9M$348.6Mdecreased
FMR LLC4.6M$325.7Mincreased
TCG Crossover Management, LLC3.7M$260.2Mheld
VANGUARD CAPITAL MANAGEMENT LLC3.6M$253.4Mincreased
VANGUARD PORTFOLIO MANAGEMENT LLC3.5M$249.2Mincreased
STATE STREET CORP3.2M$229.3Mdecreased
PRICE T ROWE ASSOCIATES INC /MD/3.1M$220.2Mdecreased
GEODE CAPITAL MANAGEMENT, LLC2.2M$157.8Mincreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by CGON insiders, by quarter · Form 4
-2.0M-1.0M01.0M2.0M2025 Q1: -3,0002025 Q12025 Q2: -2,0002025 Q22025 Q3: 1.3M2025 Q32025 Q4: -7,9032025 Q42026 Q1: -13.1K2026 Q12026 Q2: 342.5K2026 Q22026 Q3: -27.2K2026 Q32026 Q4: 31.8K2026 Q4

Recent Insider Transactions

95 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
Kuan ArthurChief Executive Officer · Director Purchase +30.0K $78.88 $2.4M Nov 18, 2026 Form 4 ↗
Kalofonos IsabelChief Commercial Officer Purchase +3,751 $79.75 $299K Nov 18, 2026 Form 4 ↗
POST LEONARD EDirector · Director Sale −1,000 $92.00 $92K Nov 16, 2026 Form 4 ↗
POST LEONARD EDirector · Director Sale −500 $62.48 $31K Oct 15, 2026 Form 4 ↗
POST LEONARD EDirector · Director Sale −500 $61.65 $31K Oct 15, 2026 Form 4 ↗
POST LEONARD EDirector Sale −1,000 $72.98 $73K Sep 15, 2026 Form 4 ↗
POST LEONARD EDirector Option exercise +1,000 $0.60 $600 Sep 15, 2026 Form 4 ↗
POST LEONARD EDirector Sale −1,000 $74.54 $75K Aug 14, 2026 Form 4 ↗
POST LEONARD EDirector Option exercise +1,000 $0.60 $600 Aug 14, 2026 Form 4 ↗
POST LEONARD EDirector Sale −1,000 $71.17 $71K Jul 15, 2026 Form 4 ↗
POST LEONARD EDirector Option exercise +1,000 $0.60 $600 Jul 15, 2026 Form 4 ↗
Mulay JamesDirector Sale −24.2K $75.16 $1.8M Jul 10, 2026 Form 4 ↗
Mulay JamesDirector Option exercise +24.2K $26.63 $644K Jul 10, 2026 Form 4 ↗
Liu Brian Guan-ChyunDirector Purchase +371.1K $66.87 $24.8M Jun 25, 2026 Form 4 ↗
POST LEONARD EDirector Sale −5,000 $70.00 $350K Jun 24, 2026 Form 4 ↗
POST LEONARD EDirector Option exercise +5,000 $0.60 $3K Jun 24, 2026 Form 4 ↗
POST LEONARD EDirector Sale −5,000 $65.00 $325K Jun 22, 2026 Form 4 ↗
POST LEONARD EDirector Option exercise +5,000 $0.60 $3K Jun 22, 2026 Form 4 ↗
Mulay JamesDirector Sale −1,310 $60.12 $79K Jun 15, 2026 Form 4 ↗
Mulay JamesDirector Option exercise +1,310 $12.59 $16K Jun 15, 2026 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding CGON · SEC Form N-PORT
FundSharesValue% of fundAs of
VANGUARD HEALTH CARE FUND
VANGUARD SPECIALIZED FUNDS
2.9M$203.6M0.53%Jul 31, 2026
T. Rowe Price Capital Appreciation Fund
T. ROWE PRICE CAPITAL APPRECIATION FUND, INC.
2.6M$182.9M0.26%Jun 30, 2026
VANGUARD TOTAL STOCK MARKET INDEX FUND
VANGUARD INDEX FUNDS
2.4M$169.3M0.01%Jun 30, 2026
iShares Russell 2000 ETF
iShares Trust
1.9M$134.6M0.16%Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF
SPDR SERIES TRUST
1.8M$128.8M1.20%Jun 30, 2026
VANGUARD SMALL-CAP INDEX FUND
VANGUARD INDEX FUNDS
1.7M$122.2M0.06%Jun 30, 2026
T. Rowe Price New Horizons Fund, Inc.1.1M$79.2M0.54%Jun 30, 2026
VANGUARD EXTENDED MARKET INDEX FUND
VANGUARD INDEX FUNDS
860.0K$61.1M0.06%Jun 30, 2026
Fidelity Small Cap Index Fund
Fidelity Salem Street Trust
806.8K$57.4M0.17%Jul 31, 2026
Fidelity Small Cap Growth Fund
Fidelity Securities Fund
797.4K$56.8M0.65%Jul 31, 2026

Mutual funds and ETFs whose N-PORT filings list CGON's shares (CUSIP 156944100), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • Roderick WongSCHEDULE 13G/A · passive (13G) · 8.5M shares9.7%
    Aug 14, 2026 · ↗
  • RTW Investments, LPSCHEDULE 13G/A · passive (13G) · 8.5M shares9.7%
    Aug 14, 2026 · ↗
  • James B. TananbaumSCHEDULE 13G/A · passive (13G) · 4.3M shares4.9%
    Aug 14, 2026 · ↗
  • Foresite Capital Management VI LLCSCHEDULE 13G/A · passive (13G) · 2.4M shares2.7%
    Aug 14, 2026 · ↗
  • Foresite Capital Fund VI LPSCHEDULE 13G/A · passive (13G) · 2.4M shares2.7%
    Aug 14, 2026 · ↗
  • Foresite Capital Opportunity Management V, LLCSCHEDULE 13G/A · passive (13G) · 857.5K shares1.0%
    Aug 14, 2026 · ↗
  • Foresite Capital Opportunity Fund V, L.P.SCHEDULE 13G/A · passive (13G) · 857.5K shares1.0%
    Aug 14, 2026 · ↗
  • Foresite Capital Management V, LLCSCHEDULE 13G/A · passive (13G) · 1.1M shares1.2%
    Aug 14, 2026 · ↗
  • Foresite Capital Fund V, L.P.SCHEDULE 13G/A · passive (13G) · 1.1M shares1.2%
    Aug 14, 2026 · ↗
  • Wellington Management Company LLPSCHEDULE 13G/A · passive (13G) · 5.3M shares5.7%
    Aug 13, 2026 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming CG Oncology, Inc. as client

No lobbying filings found naming CG Oncology, Inc. as the client.

Government Contracts

Federal awards to CG Oncology, Inc. · USAspending

No federal contract awards found for CG Oncology, Inc..

U.S. Patents

Recent USPTO applications naming CG Oncology, Inc.

No USPTO patent applications found for CG Oncology, Inc..

Annual Financials

From CGON's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023
Operating income-$190.8M-$114.7M-$55.4M
Net income-$161.0M-$88.0M-$48.6M
Diluted EPS-$2.08-$1.41-$15.65
Operating cash flow-$132.3M-$78.7M-$45.7M
Cash and equivalents$32.5M$257.1M$8.3M
Total assets$791.6M$754.8M$199.3M
Total liabilities$39.0M$21.4M$14.5M
Shareholders' equity$752.6M$733.4M-$123.1M

As CG Oncology, Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 27, 2026 ↗

Stock Splits

Every split and reverse split in the price history

No stock splits in CGON's price history.

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsNov 16, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsNov 6, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 8.01, 9.01Results of operations · Other eventsAug 6, 2026
    EDGAR ↗
  • 8-K · Items 5.07Shareholder voteJun 8, 2026
    EDGAR ↗
  • 8-K · Items 5.02Officer / director changeMay 26, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsMay 8, 2026
    EDGAR ↗

About CG Oncology, Inc.

From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersDALLAS, TX
IncorporatedDE